Zeitschriftenartikel zum Thema „Kallikrein-Related peptidase 5“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Kallikrein-Related peptidase 5" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Ismail, Maha Imam Ahmed, *. Manal Basyouni Ahmed * Manal Basyouni Ahmed und Muneera Al-Sheeha. „Evaluation of kallikrein-related peptidase 5 [KLK5] and Survivin as Prognostic Markers in Breast Cancer“. International Journal of Scientific Research 3, Nr. 5 (01.06.2012): 398–401. http://dx.doi.org/10.15373/22778179/may2014/124.
Der volle Inhalt der QuelleZingkou, Eleni, Georgios Pampalakis und Georgia Sotiropoulou. „Exacerbated dandruff in the absence of kallikrein‐related peptidase 5 protease“. Journal of Dermatology 47, Nr. 3 (07.01.2020): 311–13. http://dx.doi.org/10.1111/1346-8138.15174.
Der volle Inhalt der QuelleSidiropoulos, Konstantinos G., Nicole M. A. White, Anna Bui, Qiang Ding, Peter Boulos, Georgios Pampalakis, Heba Khella, Joseph N. Samuel, Georgia Sotiropoulou und George M. Yousef. „Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer“. Oncoscience 1, Nr. 11 (24.10.2014): 709–24. http://dx.doi.org/10.18632/oncoscience.91.
Der volle Inhalt der QuelleMalachias, Apostolos, Georgia Papachristopoulou, Dimitrios Kypraios, Stefanos P. Bassioukas, Maria Nikaki, Dimitrios Xinopoulos und Maroulio Talieri. „Sa1973 Analysis and Clinical Evaluation of Kallikrein-Related Peptidase 5 (KLK5) in Colon Cancer“. Gastroenterology 148, Nr. 4 (April 2015): S—372. http://dx.doi.org/10.1016/s0016-5085(15)31246-4.
Der volle Inhalt der QuelleOrtloff, A., F. A. Bustamante, L. Molina, J. Ojeda, C. D. Figueroa und P. Ehrenfeld. „Kallikrein-related Peptidase 5 (KLK5) Expression and Distribution in Canine Cutaneous Squamous Cell Carcinoma“. Journal of Comparative Pathology 174 (Januar 2020): 113–19. http://dx.doi.org/10.1016/j.jcpa.2019.11.009.
Der volle Inhalt der QuelleSakabe, Jun-ichi, Mami Yamamoto, Satoshi Hirakawa, Akira Motoyama, Isao Ohta, Kazuki Tatsuno, Taisuke Ito, Kenji Kabashima, Toshihiko Hibino und Yoshiki Tokura. „Kallikrein-related Peptidase 5 Functions in Proteolytic Processing of Profilaggrin in Cultured Human Keratinocytes“. Journal of Biological Chemistry 288, Nr. 24 (29.04.2013): 17179–89. http://dx.doi.org/10.1074/jbc.m113.476820.
Der volle Inhalt der QuelleLin, Yongbo, Li Ma, Hanliang Dan, Gang Chen, Jian Dai, Liang Xu und Yuqi Liu. „MiR-107-3p Knockdown Alleviates Endothelial Injury in Sepsis via Kallikrein-Related Peptidase 5“. Journal of Surgical Research 292 (Dezember 2023): 264–74. http://dx.doi.org/10.1016/j.jss.2023.07.013.
Der volle Inhalt der QuelleYoon, Hyesook, und Isobel A. Scarisbrick. „Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis“. Biological Chemistry 397, Nr. 12 (01.12.2016): 1277–86. http://dx.doi.org/10.1515/hsz-2016-0239.
Der volle Inhalt der QuelleWu, Yanhua, Yingjian Chen, Qing Li, Yanwen Gong, Xiaohong Liu, Liquan Bi und Chengjin Hu. „Upregulation of kallikrein-related peptidase 5 is associated with the malignant behavior of colorectal cancer“. Molecular Medicine Reports 14, Nr. 3 (13.07.2016): 2164–70. http://dx.doi.org/10.3892/mmr.2016.5516.
Der volle Inhalt der QuellePetraki, Constantina, Youssef M. Youssef, William Dubinski, Zsuzsanna Lichner, Andreas Scorilas, Maria D. Pasic, Vassilios Komborozos et al. „Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer“. Tumor Biology 33, Nr. 4 (22.03.2012): 1209–14. http://dx.doi.org/10.1007/s13277-012-0368-5.
Der volle Inhalt der QuelleMagnen, Mélia, Brigitta Margit Elsässer, Olga Zbodakova, Petr Kasparek, Fabien Gueugnon, Agnès Petit-Courty, Radislav Sedlacek, Peter Goettig und Yves Courty. „Kallikrein-related peptidase 5 and seasonal influenza viruses, limitations of the experimental models for activating proteases“. Biological Chemistry 399, Nr. 9 (25.09.2018): 1053–64. http://dx.doi.org/10.1515/hsz-2017-0340.
Der volle Inhalt der QuelleMontenegro, Sara Estefania, Jang-Hee Oh, Joong Heon Suh, Je-Ho Mun und Jin Ho Chung. „Higher Expression of Lympho-epithelial Kazal-type-Related Inhibitor-1 Fragments and Decreased Desquamation in the Lesional Skin of Nummular Eczema“. Acta Dermato-Venereologica 104 (29.03.2024): adv188636. http://dx.doi.org/10.2340/actadv.v104.18636.
Der volle Inhalt der QuelleNohara, Kyoko, Kazuhiko Yamada, Leo Yamada, Teruki Hagiwara, Toru Igari, Chizu Yokoi, Daisuke Soma, Satoshi Yamashita, Taeko Dohi und Yuki I. Kawamura. „Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma“. General Thoracic and Cardiovascular Surgery 66, Nr. 6 (26.03.2018): 351–57. http://dx.doi.org/10.1007/s11748-018-0910-5.
Der volle Inhalt der QuelleLee, Chia-Yao, David Marzan, Grace Lin, Steve Goodison und Steve Silletti. „α2 Integrin-Dependent Suppression of Pancreatic Adenocarcinoma Cell Invasion Involves Ectodomain Regulation of Kallikrein-Related Peptidase-5“. Journal of Oncology 2011 (2011): 1–15. http://dx.doi.org/10.1155/2011/365651.
Der volle Inhalt der Quellede Veer, Simon J., Joakim E. Swedberg, Maria Brattsand, Judith A. Clements und Jonathan M. Harris. „Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors“. Biological Chemistry 397, Nr. 12 (01.12.2016): 1237–49. http://dx.doi.org/10.1515/hsz-2016-0112.
Der volle Inhalt der QuellePapachristopoulou, Georgia, Apostolos Malachias, Marina Devetzi, Evdoxia Kamouza, Andreas Scorilas, Dimitris Xynopoulos und Maroulio Talieri. „Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence“. Clinical Chemistry and Laboratory Medicine (CCLM) 57, Nr. 8 (26.07.2019): 1251–60. http://dx.doi.org/10.1515/cclm-2018-1010.
Der volle Inhalt der QuelleBandiera, Elisabetta, Laura Zanotti, Eliana Bignotti, Chiara Romani, Renata Tassi, Paola Todeschini, Germana Tognon et al. „Human Kallikrein 5: An Interesting Novel Biomarker in Ovarian Cancer Patients That Elicits Humoral Response“. International Journal of Gynecologic Cancer 19, Nr. 6 (Juli 2009): 1015–21. http://dx.doi.org/10.1111/igc.0b013e3181ab597f.
Der volle Inhalt der QuellePampalakis, Georgios, Eleni Zingkou und Georgia Sotiropoulou. „KLK5, a novel potential suppressor of vaginal carcinogenesis“. Biological Chemistry 399, Nr. 9 (25.09.2018): 1107–11. http://dx.doi.org/10.1515/hsz-2017-0302.
Der volle Inhalt der QuelleFurio, Laetitia, Simon de Veer, Madeleine Jaillet, Anais Briot, Aurelie Robin, Celine Deraison und Alain Hovnanian. „Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome“. Journal of Experimental Medicine 211, Nr. 3 (17.02.2014): 499–513. http://dx.doi.org/10.1084/jem.20131797.
Der volle Inhalt der QuelleWu, Yanhua, Xiaofei Liu, Yingjian Chen und Chengjin Hu. „Development and evaluation of an ELISA method for the measurement of kallikrein-related peptidase 5 (KLK5) in human serum“. Open Journal of Clinical Diagnostics 03, Nr. 04 (2013): 159–66. http://dx.doi.org/10.4236/ojcd.2013.34029.
Der volle Inhalt der QuelleMeyer-Hoffert, Ulf, Zhihong Wu und Jens-Michael Schröder. „Identification of Lympho-Epithelial Kazal-Type Inhibitor 2 in Human Skin as a Kallikrein-Related Peptidase 5-Specific Protease Inhibitor“. PLoS ONE 4, Nr. 2 (03.02.2009): e4372. http://dx.doi.org/10.1371/journal.pone.0004372.
Der volle Inhalt der QuellePlanque, Chris, Yun-Hee Choi, Serge Guyetant, Nathalie Heuzé-Vourc'h, Laurent Briollais und Yves Courty. „Alternative Splicing Variant of Kallikrein-Related Peptidase 8 as an Independent Predictor of Unfavorable Prognosis in Lung Cancer“. Clinical Chemistry 56, Nr. 6 (01.06.2010): 987–97. http://dx.doi.org/10.1373/clinchem.2009.138917.
Der volle Inhalt der QuelleReid, Janet C., Nigel C. Bennett, Carson R. Stephens, Melanie L. Carroll, Viktor Magdolen, Judith A. Clements und John D. Hooper. „In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B“. Biological Chemistry 397, Nr. 12 (01.12.2016): 1299–305. http://dx.doi.org/10.1515/hsz-2016-0163.
Der volle Inhalt der QuelleAvgeris, Margaritis, Georgia Papachristopoulou, Athanasios Polychronis und Andreas Scorilas. „Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions“. Clinical Proteomics 8, Nr. 1 (2011): 5. http://dx.doi.org/10.1186/1559-0275-8-5.
Der volle Inhalt der QuelleWeidinger, Stephan, Hansjörg Baurecht, Stefan Wagenpfeil, John Henderson, Natalija Novak, Aileen Sandilands, Huijia Chen et al. „Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk“. Journal of Allergy and Clinical Immunology 122, Nr. 3 (September 2008): 560–68. http://dx.doi.org/10.1016/j.jaci.2008.05.050.
Der volle Inhalt der QuelleBrännström, Kristoffer, Anders Öhman, Ulrich von Pawel Rammingen, Anders Olofsson und Maria Brattsand. „Characterization of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis“. Biological Chemistry 393, Nr. 5 (01.05.2012): 369–77. http://dx.doi.org/10.1515/hsz-2011-0238.
Der volle Inhalt der QuelleFukushima, Tsuyoshi, Shuichiro Uchiyama, Hiroyuki Tanaka und Hiroaki Kataoka. „Hepatocyte Growth Factor Activator: A Proteinase Linking Tissue Injury with Repair“. International Journal of Molecular Sciences 19, Nr. 11 (01.11.2018): 3435. http://dx.doi.org/10.3390/ijms19113435.
Der volle Inhalt der QuelleNomura, Hayato, Mutsumi Suganuma, Takuya Takeichi, Michihiro Kono, Yuki Isokane, Ko Sunagawa, Mina Kobashi et al. „Multifaceted Analyses of Epidermal Serine Protease Activity in Patients with Atopic Dermatitis“. International Journal of Molecular Sciences 21, Nr. 3 (30.01.2020): 913. http://dx.doi.org/10.3390/ijms21030913.
Der volle Inhalt der QuelleIshida, Koichi, Liyue Qin, Ting Wang, Ying Lei, Weiwei Hu, Geng Zhu, Qianqian Zhuang et al. „Local mechanisms for acupoint sensitization in gall bladder meridian of foot shaoyang-a gene chip study“. Acupuncture & Electro-Therapeutics Research 44, Nr. 2 (01.06.2019): 77–87. http://dx.doi.org/10.3727/036012919x15650315071898.
Der volle Inhalt der QuelleSchaap, Mirjam J., Finola M. Bruins, Xuehui He, Kadri Orro, Malou Peppelman, Piet E. J. van Erp, Elke M. G. J. de Jong, Hans J. P. M. Koenen, Ellen H. van den Bogaard und Marieke M. B. Seyger. „Skin Surface Protein Detection by Transdermal Analysis Patches in Pediatric Psoriasis“. Skin Pharmacology and Physiology 34, Nr. 5 (2021): 271–80. http://dx.doi.org/10.1159/000516110.
Der volle Inhalt der QuelleBeaufort, Nathalie, Karolina Plaza, Daniel Utzschneider, Amelie Schwarz, Julia M. Burkhart, Sabine Creutzburg, Mekdes Debela, Manfred Schmitt, Christian Ries und Viktor Magdolen. „Interdependence of kallikrein-related peptidases in proteolytic networks“. Biological Chemistry 391, Nr. 5 (01.05.2010): 581–87. http://dx.doi.org/10.1515/bc.2010.055.
Der volle Inhalt der QuelleJung, Monika, Annika Schaefer, Isabel Steiner, Carsten Kempkensteffen, Carsten Stephan, Andreas Erbersdobler und Klaus Jung. „Robust MicroRNA Stability in Degraded RNA Preparations from Human Tissue and Cell Samples“. Clinical Chemistry 56, Nr. 6 (01.06.2010): 998–1006. http://dx.doi.org/10.1373/clinchem.2009.141580.
Der volle Inhalt der QuellePathak, Monika, Szu Shen Wong, Ingrid Dreveny und Jonas Emsley. „Structure of plasma and tissue kallikreins“. Thrombosis and Haemostasis 110, Nr. 09 (2013): 423–33. http://dx.doi.org/10.1160/th12-11-0840.
Der volle Inhalt der QuelleChee, Jessica, Jasmine Singh, Anupam Naran, Neil L. Misso, Philip J. Thompson und Kanti D. Bhoola. „Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma“. Biological Chemistry 388, Nr. 11 (01.11.2007): 1235–42. http://dx.doi.org/10.1515/bc.2007.139.
Der volle Inhalt der QuelleSarwar, Md Shahid, Christina N. Ramirez, Hsiao-Chen Dina Kuo, Pochung Chou, Renyi Wu, Davit Sargsyan, Ahmad Shannar et al. „Abstract 5266: Metabolic rewiring and epigenetic reprogramming by the environmental carcinogen benzo[a]pyrene in a two-stage skin carcinogenesis mouse model and cancer interception by triterpenoid ursolic acid“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 5266. http://dx.doi.org/10.1158/1538-7445.am2023-5266.
Der volle Inhalt der QuelleHamilton, Brian S., und Gary R. Whittaker. „Cleavage Activation of Human-adapted Influenza Virus Subtypes by Kallikrein-related Peptidases 5 and 12“. Journal of Biological Chemistry 288, Nr. 24 (23.04.2013): 17399–407. http://dx.doi.org/10.1074/jbc.m112.440362.
Der volle Inhalt der QuelleWang, Ping, Viktor Magdolen, Christof Seidl, Julia Dorn, Enken Drecoll, Matthias Kotzsch, Feng Yang et al. „Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer“. British Journal of Cancer 119, Nr. 7 (Oktober 2018): 1–9. http://dx.doi.org/10.1038/s41416-018-0260-1.
Der volle Inhalt der QuelleKeuylian, Zela, und Alain Hovnanian. „Mechanistic insight from murine models of Netherton syndrome“. Biological Chemistry 397, Nr. 12 (01.12.2016): 1223–28. http://dx.doi.org/10.1515/hsz-2016-0203.
Der volle Inhalt der QuelleOlkhov, E., T. H. Van Der Kwast, K. Kron, V. Pethe, H. Ozcelik, L. Briollais, N. E. Fleshner, E. P. Diamandis, A. R. Zlotta und B. Bapat. „543 Methylation of Kallikrein-related peptidases as novel diagnostic and prognostic biomarkers for prostate cancer“. European Urology Supplements 11, Nr. 1 (Februar 2012): e543-e543a. http://dx.doi.org/10.1016/s1569-9056(12)60540-5.
Der volle Inhalt der QuelleEhrenfeld, Pamela, Carlos D. Figueroa, Luis Molina, Tania Koning, Myriam Velasco, Felipe A. Bustamante-Barrientos und Alexander Ortloff. „Expression and Distribution of Kallikrein-related Peptidases 5, 7, 8 and 10 in Normal Apocrine Gland of Canine Skin“. International Journal of Morphology 41, Nr. 1 (Februar 2023): 210–15. http://dx.doi.org/10.4067/s0717-95022023000100210.
Der volle Inhalt der QuelleShahinian, Hasmik, Daniela Loessner, Martin L. Biniossek, Jayachandran N. Kizhakkedathu, Judith A. Clements, Viktor Magdolen und Oliver Schilling. „Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells“. Molecular Oncology 8, Nr. 1 (01.10.2013): 68–82. http://dx.doi.org/10.1016/j.molonc.2013.09.003.
Der volle Inhalt der QuelleJendrny, Cathleen, und Annette G. Beck-Sickinger. „Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor-1 (SFTI-1)“. ChemBioChem 17, Nr. 8 (22.12.2015): 719–26. http://dx.doi.org/10.1002/cbic.201500539.
Der volle Inhalt der QuelleBarabe, J., D. Huberdeau und A. Bernoussi. „Influence of sodium balance on urinary excretion of immunoreactive kinins in rats“. American Journal of Physiology-Renal Physiology 254, Nr. 4 (01.04.1988): F484—F491. http://dx.doi.org/10.1152/ajprenal.1988.254.4.f484.
Der volle Inhalt der QuelleThomadaki, Hellinida, Konstantinos Mavridis, Maroulio Talieri und Andreas Scorilas. „Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11“. Thrombosis and Haemostasis 101, Nr. 02 (2009): 373–80. http://dx.doi.org/10.1160/th08-01-0025.
Der volle Inhalt der QuelleJendrny, Cathleen, und Annette G. Beck-Sickinger. „Inside Back Cover: Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor-1 (SFTI-1) (ChemBioChem 8/2016)“. ChemBioChem 17, Nr. 8 (05.04.2016): 784. http://dx.doi.org/10.1002/cbic.201600146.
Der volle Inhalt der QuelleChavakis, Triantafyllos, Sandip M. Kanse, Florea Lupu, Hans-Peter Hammes, Werner Müller-Esterl, Robin A. Pixley, Robert W. Colman und Klaus T. Preissner. „Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor–dependent interactions“. Blood 96, Nr. 2 (15.07.2000): 514–22. http://dx.doi.org/10.1182/blood.v96.2.514.
Der volle Inhalt der QuelleChavakis, Triantafyllos, Sandip M. Kanse, Florea Lupu, Hans-Peter Hammes, Werner Müller-Esterl, Robin A. Pixley, Robert W. Colman und Klaus T. Preissner. „Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor–dependent interactions“. Blood 96, Nr. 2 (15.07.2000): 514–22. http://dx.doi.org/10.1182/blood.v96.2.514.014k45_514_522.
Der volle Inhalt der QuelleLuo, Yanmin, Premlata Kumar und Carole R. Mendelson. „Estrogen-Related Receptor γ (ERRγ) Regulates Oxygen-Dependent Expression of Voltage-gated Potassium (K+) Channels and Tissue Kallikrein during Human Trophoblast Differentiation“. Molecular Endocrinology 27, Nr. 6 (01.06.2013): 940–52. http://dx.doi.org/10.1210/me.2013-1038.
Der volle Inhalt der QuelleBandiera, Elisabetta, Laura Zanotti, Eliana Bignotti, Chiara Romani, Renata Tassi, Paola Todeschini, Germana Tognon et al. „Human Kallikrein 5: An Interesting Novel Biomarker in Ovarian Cancer Patients that Elicits a Humoral Response“. International Journal of Biological Markers 24, Nr. 3 (Juli 2009): 211. http://dx.doi.org/10.1177/172460080902400337.
Der volle Inhalt der QuelleDong, Y., L. T. Bui, D. M. Odorico, O. L. Tan, S. A. Myers, H. Samaratunga, R. A. Gardiner und J. A. Clements. „Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms“. Endocrine-Related Cancer 12, Nr. 4 (Dezember 2005): 875–89. http://dx.doi.org/10.1677/erc.1.01062.
Der volle Inhalt der Quelle